刘晔弘主治医师作为一名医学科研工作者，本科及硕士研究生均毕业于上海交通大学美高梅，曾于瑞金医院进行医师规范化培训；毕业之后进入美高梅附属东方医院心血管内科从事临床及研究工作，目前专注于从事心脏瓣膜病的分子机制研究，以第一作者在JAHA、ESC Heart Failure.、Frontier Cardiovascular Medicine等国际SCI杂志发表论文多篇SCI论文；2007年及2018年曾分别于香港威尔士亲王医院及内布拉斯加医学中心访学交流；目前主持国家自然科学基金一项，参与多项国自然面上项目、上海市浦江人才计划等；除基础科研以外还致力于心血管疾病转化研究，申请相关转化专利一项。
I, doctor Liu Ye-hong , graduated from Shanghai Jiao Tong University School of Medicine with a bachelor's degree and a master's degree. I also received standardized training in Ruijin Hospital. After graduation, I entered the Department of Cardiology of East Hospital Affiliated to Tongji University and engaged in clinical and research work since 2014. My research work mainly focused on the molecular mechanism of valvular heart disease. Published several papers in international SCI journals such as JAHA, ESC Heart Failure, Frontier Cardiovascular Medicine as the first author. In 2007 and 2018, I visited the Prince of Wales Hospital in Hong Kong and Nebraska Medical Center respectively. At present, I have presided over a National Natural Science Foundation and participated in a number of national natural surface projects and Shanghai Pujiang Talent Plan. In addition to basic scientific research, I also committed to translational research on cardiovascular diseases, and have applied a related translational patent.
主持科研项目：
国家自然科学基金青年项目，82100381，Leptin诱导主动脉瓣内皮细胞成骨分化促进瓣膜钙化早期病变的机制研究。
专利项目：一种分段多向可控弯导管
Presiding over scientific research projects:
Youth Project of National Natural Science Foundation of China, 82100381, Study on the mechanism of osteogenic differentiation of aortic valve endothelial cells induced by Leptin to promote the early stage of valve calcification.
Patent project: a segmented multi-directional controllable curved conduit
参与科研项目：
1. 上海市浦江人才计划D类，22PJD044，FSTL1调控主动脉瓣膜钙化病变机制的研究，在研
2. 国家自然科学基金面上项目，82070401，钙化性主动脉瓣膜病中FSTL3促主动脉瓣膜间质细胞钙化的机制研究，在研
3. 国家自然科学基金面上项目，81770384，FSTL1介由DIP2A/CD14对抗主动脉瓣钙化的机制研究，已结题
Participate in research projects:
1. Shanghai Pujiang Talent Program, Class D, 22PJD044, Study on the mechanism of FSTL1 regulation of aortic valve calcification, in progress
2. National Natural Science Foundation of China, 82070401, Study on the mechanism of FSTL3 promoting the calcification of aortic valve interstitial cells in calcifying aortic valvular disease, in progress
3. National Natural Science Foundation of China, 81770384, Mechanism study of FSTL1 mediated by DIP2A/CD14 against aortic valve calcification, completed
主要发表文章：
2023年
1. Lin B, Shen Y, Zhang P, Shen Y, Gu Y, He X, Li J, Yang K, Shen W, Zhang Q, Xin Y and Liu Y. Prognostic role of tissue plasminogen activator in coronary artery disease with or without aortic valve sclerosis. ESC Heart Fail. 2023.
2. Liu YH, Liu Y, Xin YF, Zhang Q and Ding ML. Identification of key genes involved in calcific aortic valve disease based on integrated bioinformatics analysis. Exp Biol Med (Maywood). 2023;248:52-60.
2021年
刘晔弘 张奇*；冠状动脉钙化的临床研究进展；国际心血管病杂志[J]；2021， 6（48）337-340
2020年
Chen Z, Shen Y, Xue Q, Lin BW, He XY, Zhang YB, Yang Y, Shen WF, Liu YH and Yang K. Clinical Relevance of Plasma Endogenous Tissue-Plasminogen Activator and Aortic Valve Sclerosis: Performance as a Diagnostic Biomarker. Front Cardiovasc Med. 2020;7:584998.
2019年
Liu Y, Gu Y, Shen Y, Lin B, Li Y, He X, Zhang Y, Lu L, Shen W, Zhang Q and Yang K. Association Between Serum Leptin Level and Calcific Aortic Valve Disease. J Am Heart Assoc. 2019;8:e012495
2016年
刘晔弘; 范骎; 张凤如; 陆林; 沈卫峰; 陶蓉*；S1P受体激动剂FTY720在大鼠非梗死区心肌组织中的作用；上海交通大学学报 (医学报) [J]；2016, 36(9): 1271-1277.
2012年
Liu YH, Su JY, Wang LJ, Li JP, Zhou QF, Gan Q, Chai XC, Dai LY, Zhang FR and Shen WF. Impact of potentially lethal ventricular arrhythmias on long-term outcome in patients with chronic heart failure. Chin Med J (Engl). 2012;125:563-8.
2010年
刘晔弘; 张凤如；松弛素在急性心力衰竭治疗中的作用；国际心血管病杂志[J]；2010, 1(37): 21-23
